Sutro Biopharma Announces Additions to Board of Directors and Senior Management Team
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Sutro Biopharma, Inc., the leader in open cell-free synthesis (OCFS) for the discovery and production of proteins, today announced several key appointments to the company's management. Daniel H. Petree of P2 Partners, LLC has been elected to the Sutro board of directors. The company has also named Henry Heinsohn, former senior scientist in process development at Genentech, as vice president of development and manufacturing, and Lesley Stolz, Ph.D., former vice president, corporate and business development at Sunesis Pharmaceuticals, as vice president of business development.
"Dan Petree brings to our board a wealth of experience in both deal making and financing emerging biotechnology companies," said William J. Newell, Sutro Biopharma's chief executive officer. "Dan's almost two decades of experience leading transactions and fundraising as a principal of P(2) Partners, as president and chief operating officer of Axys Pharmaceuticals, and as an investment banker in the life sciences sector, will be a very important resource for us to tap into as we actively pursue both paths in the coming months.
"Similarly," Mr. Newell continued, "Henry Heinsohn and Lesley Stolz join Sutro Biopharma with years of senior level experience in their respective fields. Henry has over 24 years of process development and manufacturing experience related to recombinant protein production and was responsible for developing the large scale protein recovery processes for a number of Genentech's novel protein therapeutics. Lesley has 15 years of business development experience for both technology platform and therapeutics focused companies and has numerous connections throughout the pharmaceutical and biotechnology industries. We welcome them both to the Sutro Biopharma management team, where we expect them to play important roles in advancing our company to the next stage in its development."
Henry Heinsohn Biography
Mr. Heinsohn joins Sutro Biopharma following 17 years previous employment at Genentech, where he held the role of senior scientist and senior group leader for process development, early stage purification activities. While at Genentech, he developed large-scale protein recovery processes, supported research and development activities and participated in regulatory filings for VEGF, thrombopoeitin, Lucentis(R), and other novel protein therapeutics. He was CMC team leader for the development and launch of Avastin(R). Prior to joining Genentech, Henry was employed by Genencor International where he was senior scientist. Previously, he was a scientist at Corning Medical and Scientific. Henry received a B.S. in Chemistry from North Carolina State University, and conducted postgraduate studies in Biochemistry at the Boston University.
Lesley Stolz, Ph.D. Biography
Dr. Stolz joins Sutro Biopharma from Sunesis Pharmaceuticals where she was vice president, corporate & business development. Prior to Sunesis, she led business development for Aerovance, Inc. Lesley was senior director, business development for GPC Biotech AG of Germany from 2002 to 2006. She also served as director, business development for Cell Genesys, Inc. Dr. Stolz received her Ph.D. and M.S. degrees from the University of Rochester and a B.S. from the University of Virginia. She conducted postdoctoral research at Harvard Medical School's Department of Biochemistry and Molecular Pharmacology.
About Sutro Biopharma, Inc.
Sutro Biopharma, Inc. is a biopharmaceutical company that uses its patented technology collaboratively for the discovery and production of novel biomedicines for the treatment of human disease. The company's technology is applicable to a wide variety of novel therapeutic proteins, including cytokines, antibody fragments, Fc fusions, membrane proteins and enzymes.
For more information on Sutro Biopharma, please visit our website at http://www.sutrobio.com.
Source: Sutro Biopharma, Inc.
Released August 20, 2009